GtoPdb is requesting financial support from commercial users. Please see our sustainability page for more information.
| 
                               
                            
                                
                                                                Synonyms: (S)-(+)-Ketamine | (S)-Ketamine | Spravato®
                                 
                                                         
                            
                            
                            
                                 
                                
                                esketamine is an approved drug (EMA & FDA (2019)) 
                                                        
                                                    
                                Compound class: 
                                                            Synthetic organic
                                 
                                
                                    
                                        Comment: As the ketamine (S) enatiomer esketamine is twice as potent and has a more medically useful pharmacological action than racemic ketamine. Part of this advantage arises from inhibition of dopamine transporters.
                                    
                                 
                            
                            
                          
                                
                                    
                                
                          
                                   
                                   
                                  
                                    
                                    
                                     | 
                                    
                                        
                                         
  | 
                                    
                                
                                |||||||||||||||||||||||||||||||||||
| References | 
| 
                                                                         1. Kang H, Epstein M, Banke TG, Perszyk R, Simorowski N, Paladugu S, Liotta DC, Traynelis SF, Furukawa H. (2025)
                                         Structural basis for channel gating and blockade in tri-heteromeric GluN1-2B-2D NMDA receptor. Neuron, 113 (7): 991-1005.e5. [PMID:39954679]  | 
                                                                
| 
                                                                         2. Yi F, Bhattacharya S, Thompson CM, Traynelis SF, Hansen KB. (2019)
                                         Functional and pharmacological properties of triheteromeric GluN1/2B/2D NMDA receptors. J Physiol, 597 (22): 5495-5514. [PMID:31541561]  |